Search

Your search keyword '"Drusch, Françoise"' showing total 15 results
Start Over Author "Drusch, Françoise"
15 results on '"Drusch, Françoise"'

2. Refinement of high-risk endometrial cancer classification using DNA damage response biomarkers: a TransPORTEC initiative

Author

Auguste, Aurélie, Genestie, Catherine, De Bruyn, Marco, Adam, Julien, Le Formal, Audrey, Drusch, Françoise, Pautier, Patricia, Crosbie, Emma J., MacKay, Helen, Kitchener, Henry C., Powell, Melanie, Pollock, Pamela M., Mileshkin, Linda, Edmondson, Richard J., Nout, Remi, Nijman, Hans W., Creutzberg, Carien L., Bosse, Tjalling, and Leary, Alexandra

Published
2018
Full Text
View/download PDF

6. Neoadjuvant chemotherapy alters the balance of effector to suppressor immune cells in advanced ovarian cancer

Author

Leary, Alexandra, primary, Genestie, Catherine, additional, Blanc-Durand, Félix, additional, Gouy, Sébastien, additional, Dunant, Ariane, additional, Maulard, Amandine, additional, Drusch, Françoise, additional, Cheaib, Bianca, additional, Michels, Judith, additional, Bentivegna, Enrica, additional, LeFormal, Audrey, additional, Mesnage, Soizick, additional, Morice, Philippe, additional, Pautier, Patricia, additional, and Khairallah, Aya S., additional

Published
2020
Full Text
View/download PDF

7. Adipose Tissue Properties in Tumor-Bearing Breasts

Author

Miran, Isabelle, primary, Scherer, Dominique, additional, Ostyn, Pauline, additional, Mazouni, Chafika, additional, Drusch, Françoise, additional, Bernard, Marine, additional, Louvet, Emilie, additional, Adam, Julien, additional, Mathieu, Marie-Christine, additional, Haffa, Mariam, additional, Antignac, Jean-Philippe, additional, Le Bizec, Bruno, additional, Vielh, Philippe, additional, Dessen, Philippe, additional, Perdry, Hervé, additional, Delaloge, Suzette, additional, and Feunteun, Jean, additional

Published
2020
Full Text
View/download PDF

8. Topoisomerase II-alpha protein expression and histological response following doxorubicin-based induction chemotherapy predict survival of locally advanced soft tissues sarcomas

Author

Blay Jean-Yves, Boulet Bérénice, Gomez-Abuin Gonzalo, Bénard Jean, Cioffi Angela, Le Cesne Axel, Tournay Elodie, Terrier Philippe, Ruiz-Soto Rodrigo, Domont Julien, Drusch Françoise, Auger Nathalie, Coindre Jean-Michel, and Bonvalot Sylvie

Subjects
Adult, Male, Oncology, Cancer Research, Prognostic variable, Pathology, medicine.medical_specialty, Adolescent, Receptor, ErbB-2, medicine.medical_treatment, Antineoplastic Agents, Soft Tissue Neoplasms, Biology, Disease-Free Survival, Antigens, Neoplasm, Recurrence, Internal medicine, medicine, Humans, Doxorubicin, Aged, Retrospective Studies, Chemotherapy, Soft tissue sarcoma, Cancer, Induction chemotherapy, Sarcoma, Middle Aged, Endonucleases, Prognosis, medicine.disease, Immunohistochemistry, DNA-Binding Proteins, Gene Expression Regulation, Neoplastic, DNA Topoisomerases, Type II, Treatment Outcome, Female, ERCC1, medicine.drug
Abstract

Purpose Neoadjuvant chemotherapy for locally advanced soft tissue sarcomas (LASTS), although not standard, represents a promising option for resectable tumours. Current lack of biological predictors of chemotherapy response led us to establish a relationship between Topoisomerase II-alpha (Topo2A), HER2, excision repair cross-complementing group 1 (ERCC1) protein expression, histological response and clinical outcomes of LASTS patients. Patients and methods A retrospective study based on clinical data and archival paraffin-embedded tumour tissue at diagnosis from 78 consecutive LASTS patients treated with neo-adjuvant chemotherapy in our institution enabled analysis of ERCC1, HER2 and Topo2A protein expression by immuno-histochemistry. Results Disease free survival (DFS) and overall survival (OS) were 48% and 64%, respectively. The annual risk of relapse increased with a higher percentage of residual identifiable cells (RIC). A higher Topo2A protein was associated with an improved rate of good HR (r = 0.416) and with a decreased risk of relapse. Median DFS decreased with low Topo2A (p ⩽ 0.042). The ERCC1 status had no impact on histological response while ERCC1 positive tumours correlated with a favourable OS (p ⩽ 0.058). Patients with LASTS co-expressing Topo2A and ERCC1 had a significant better outcome (p = 0.018). Topo2A was the only independent variable linked to a good HR (p ⩽ 0.017); histological grade 3 was the only independent adverse prognostic variable linked to both DFS (p ⩽ 0.04) and OS (p ⩽ 0.004). Conclusions While histological response predicts better DFS, Topo2A protein expression correlates with histological response and better DFS. The combination of an early predictive factor for chemosensitivity (Topo2A) and for survival (ERCC1) highlights the possibility to develop individualised therapeutic approaches (CONTICANET program).

Published
2011

9. Expression of EPHRIN-A1, SCINDERIN and MHC class I molecules in head and neck cancers and relationship with the prognostic value of intratumoral CD8+T cells

Author

Hasmim, Meriem, primary, Badoual, Cécile, additional, Vielh, Philippe, additional, Drusch, Françoise, additional, Marty, Virginie, additional, Laplanche, Agnès, additional, de Oliveira Diniz, Mariana, additional, Roussel, Hélène, additional, De Guillebon, Eléonore, additional, Oudard, Stéphane, additional, Hans, Stéphane, additional, Tartour, Eric, additional, and Chouaib, Salem, additional

Published
2013
Full Text
View/download PDF

10. Oropharyngeal cancers: Significance of HPV16 detection in neck lymph nodes

Author

Mirghani, Haïtham, primary, Ferchiou, Malek, additional, Moreau, Frederique, additional, Vourexakis, Zacharias, additional, Amen, Furrat, additional, Breuskin, Ingrid, additional, Lefèvre, Marine, additional, Casiraghi, Odile, additional, Drusch, Françoise, additional, Soussan, Patrick, additional, Vielh, Philippe, additional, and St Guily, Jean Lacau, additional

Published
2013
Full Text
View/download PDF

12. Circulating Tumor Cells in Lung Cancer

Author

Young, Rachel, primary, Pailler, Emma, additional, Billiot, Fanny, additional, Drusch, Françoise, additional, Barthelemy, Amélie, additional, Oulhen, Marianne, additional, Besse, Benjamin, additional, Soria, Jean-Charles, additional, Farace, Françoise, additional, and Vielh, Philippe, additional

Published
2012
Full Text
View/download PDF

13. Portrait of Ependymoma Recurrence in Children: Biomarkers of Tumor Progression Identified by Dual-Color Microarray-Based Gene Expression Analysis

Author

Peyre, Matthieu, primary, Commo, Frédéric, additional, Dantas-Barbosa, Carmela, additional, Andreiuolo, Felipe, additional, Puget, Stéphanie, additional, Lacroix, Ludovic, additional, Drusch, Françoise, additional, Scott, Véronique, additional, Varlet, Pascale, additional, Mauguen, Audrey, additional, Dessen, Philippe, additional, Lazar, Vladimir, additional, Vassal, Gilles, additional, and Grill, Jacques, additional

Published
2010
Full Text
View/download PDF

15. Expression of EPHRIN-A1, SCINDERIN and MHC class I molecules in head and neck cancers and relationship with the prognostic value of intratumoral CD8+ T cells.

Author

Hasmim, Meriem, Badoual, Cécile, Vielh, Philippe, Drusch, Françoise, Marty, Virginie, Laplanche, Agnès, de Oliveira Diniz, Mariana, Roussel, Hélène, De Guillebon, Eléonore, Oudard, Stéphane, Hans, Stéphane, Tartour, Eric, and Chouaib, Salem

Subjects
HEAD & neck cancer, GENE expression, CANCER patients, CELL-mediated cytotoxicity, TUMOR genetics
Abstract

Background: Our group has previously shown that EPHRIN-A1 and SCINDERIN expression by tumor cells rendered them resistant to cytotoxic T lymphocyte-mediated lysis. Whereas the prognostic value of EPHRIN-A1 expression in cancer has already been studied, the role of SCINDERIN presence remains to be established. In the present work, we investigated the prognosis value of EPHRIN-A1 and SCINDERIN expression in head and neck carcinomas. In addition, we monitored the HLA-class I expression by tumor cells and the presence of tumor-infiltrating CD8+ T cells to evaluate a putative correlation between these factors and the survival prognosis by themselves or related to EPHRIN-A1 and SCINDERIN expression.Methods: Tumor tissue sections of 83 patients with head and neck cancer were assessed by immunohistochemistry for the expression of EPHRIN-A1, SCINDERIN, HLA class I molecules and the presence of CD8+ T cells.Results: No significant prognosis value could be attributed to these factors independently, despite a tendency of association between EPHRIN-A1 and a worse clinical outcome. No prognostic value could be observed when CD8+ T cell tumor infiltration was analyzed combined with EPHRIN-A1, SCINDERIN or HLA class I expression.Conclusion: These results highlight that molecules involved in cancer cell resistance to cytotoxic T lymphocytes by themselves are not a sufficient criteria for prognosis determination in cancer patients. Other intrinsic or tumor microenvironmental features should be considered in prognostic evaluation. [ABSTRACT FROM AUTHOR]

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results